Cabaletta Bio (NASDAQ:CABA) executives told investors at the Guggenheim Emerging Outlook Biotech Summit 2026 that the company has initiated enrollment in what it described as its first pivotal program ...

About Cabaletta Bio Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...

Furthermore, H.C. Wainwright has maintained a Buy rating on Cabaletta Bio, setting a price target of $16.00, following the presentation of positive clinical data from the RESET trials. These trials, ...

Michael Gerard, General Counsel of Cabaletta Bio, Inc. (NASDAQ:CABA), recently purchased 6,600 shares of the company’s common stock. The transactions, which occurred on January 21, 2026, involved a ...

Investing.com - Guggenheim has reiterated a Buy rating and $15.00 price target on Cabaletta Bio Inc. (NASDAQ:CABA), highlighting the company’s differentiated commercial strategy for its rese-cel ...

Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.

Targeted therapies have been moved forward in the treatment of both pemphigus and pemphigoid diseases, a factor behind an urgency for rapid diagnosis.

On Oct 27, 2025, CABA reported earnings of -0.44 USD per share (EPS) for Q3 25, beating the estimate of -0.48 USD, resulting in a 8.60% surprise. Revenue reached --, compared to an expected --, with a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...